Literature DB >> 28112368

LOXL3-sv2, a novel variant of human lysyl oxidase-like 3 (LOXL3), functions as an amine oxidase.

Chankyu Jeong1, Youngho Kim1.   

Abstract

Human lysyl oxidase-like 3 (LOXL3) functions as a copper-dependent amine oxidase toward collagen and elastin. The LOXL3 protein contains four scavenger receptor cysteine-rich (SRCR) domains in the N-terminus in addition to the C-terminal characteristic domains of the lysyl oxidase (LOX) family, such as a copper-binding domain, a cytokine receptor‑like domain and residues for the lysyl-tyrosyl quinone cofactor. Using BLASTN searches, we identified a novel variant of LOXL3 (termed LOXL3-sv2), which lacked the sequences corresponding to exons 4 and 5 of LOXL3. The LOXL3-sv2 mRNA is at least 2,398 bp in length, encoding a 608 amino acid-long polypeptide with a calculated molecular mass of 67.4 kDa. The deletion of exons 4 and 5 do not change the open-reading frame of LOXL3 but results in deletion of the SRCR domain 2. The recombinant LOXL3-sv2 protein showed a β-aminopropionitrile-inhibitable amine oxidase activity toward collagen type I. In RT-PCR analysis, LOXL3-sv2 was detected in all human tissues tested, along with LOXL3 and LOXL3-sv1, a previously identified variant of LOXL3. These findings indicate that the human LOXL3 gene encodes at least three variants, LOXL3, LOXL3-sv1 and LOXL3-sv2, all of which function as amine oxidases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28112368     DOI: 10.3892/ijmm.2017.2862

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  2 in total

1.  Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability.

Authors:  Patricia G Santamaría; Alfredo Floristán; Bárbara Fontanals-Cirera; Alberto Vázquez-Naharro; Vanesa Santos; Saleta Morales; Lourdes Yuste; Héctor Peinado; Antonio García-Gómez; Francisco Portillo; Eva Hernando; Amparo Cano
Journal:  Cell Death Differ       Date:  2017-12-11       Impact factor: 15.828

2.  Targeted Deletion of Loxl3 by Col2a1-Cre Leads to Progressive Hearing Loss.

Authors:  Ziyi Liu; Xinfeng Bai; Peifeng Wan; Fan Mo; Ge Chen; Jian Zhang; Jiangang Gao
Journal:  Front Cell Dev Biol       Date:  2021-06-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.